Keyword: Scripps Research Institute
By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.
A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.
Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.
The week’s biotech news included a surgical gel that prevents tumors from spreading and an antibody against opioids.
Using broadly neutralizing single-domain antibodies from llamas, scientists have designed a vaccine that can potentially combat almost all flu viruses.
Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
Scripps researchers pinpointed a protein that can sense blood flow and prompt tiny blood vessels to dilate. It may be a target for drug development.
Understanding how some helper T cells become killer T cells could lead to better vaccine design for HIV and hep C.
The National Institutes of Health has tapped Fitbit to provide 10,000 devices for the All of Us research program.
Vividion Therapeutics seeks to deploy its synthetic and proteomic chemistry platforms to “dramatically expand” the number of targets that can be approached therapeutically. Its technology identifies previously unknown druggable targets in the human proteome.